Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Yiqi Fumai Lyophilized Injection for Chronic Heart Failure Due to Coronary Heart Disease
NCT07803471Not yet recruiting
- Sponsor
- China Academy of Chinese Medical Sciences
- Start
- Sep 2026
- Primary completion
- Jul 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial of yiqi fumai in chronic heart failure (CHF) and coronary heart disease (CHD), sponsored by China Academy of Chinese Medical Sciences. Primary endpoints: Percentage of Participants With a Kansas City Cardiomyopathy Questionnaire Clinical Summary Score Response at Day 11 and Percentage of Participants With an NT-proBNP Response at Day 11. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
yiqi fumai
03
Conditions
chronic heart failure (CHF)coronary heart disease (CHD)
Beyond the preview
Go deeper on NCT07803471.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07803471.